

## Public Statement for the Japanese Ministry of Health, Labor, and Welfare

Pharma Mar S.A. Sociedad Unipersonal, is a Spanish pharmaceutical company that is a wholly owned subsidiary of the Zeltia Group, a corporation listed on the Bolsa de Madrid (Madrid Stock Exchange). Pharma Mar was established in 1986 with the mission to find and develop anti-cancer agents from marine organisms, and currently employs 260 persons. During the 2007 fiscal year, Pharma Mar invested approximately €37 million (approximately ¥5.7 billion) in research and development activities. Pharma Mar is headquartered in Colmenar Viejo (approximately 25 km north of Madrid, Spain), and has a research facility in Cambridge, Massachusetts, USA. Pharma Mar is the first, and to date only, Spanish biopharmaceutical company that manages pharmaceutical product development from basic research, to non-clinical and clinical development, and finally to production and marketing of medicinal products.

Pharma Mar is aware that the oceans, the source of its activities, are environmentally fragile and is committed to the sustainable and environmentally sound development of marine resources. Therefore, the substances in its medicinal products are synthetic.

Pharma Mar would like to inform the Ministry of Health, Labor, and Welfare of the following information:

- Pharma Mar received European Commission authorization in September 2007 to market its first product, Yondelis (INN: trabectedin), to treat advanced soft tissue sarcomas (STSs). Yondelis is currently marketed in 10 European Union countries including Spain, and will be marketed in other EU countries soon.
- Yondelis is a DNA-binding antitumor agent with unique properties that shows *in vitro* and *in vivo* activity against a wide range of solid and hematologic malignancies.
- Pharma Mar has submitted a marketing application for STS in Switzerland and, together with its co-development partner Johnson & Johnson – Pharmaceutical Research and Development (J&J – PRD), has submitted applications in Brazil, Hong Kong, Russia, Singapore, and South Korea.
- Pharma Mar has 4 other anti-tumor compounds in clinical development, and is the sole sponsor or a co-sponsor of clinical trials on all 5 compounds. Trials are being conducted in 23 countries at 250 medical research centers in the Asia – Pacific region, Europe, North America, and South America.
- Pharma Mar expects to begin Yondelis development in Japan in 2008.

For additional information about Pharma Mar and the Zeltia Group, please visit the following web sites:

<http://www.pharmamar.com/en/about/>

<http://www.zeltia.com/>

(An English version of this site is available by clicking on “English” on the home page.)